Exact Mass: 564.3312
Exact Mass Matches: 564.3312
Found 464 metabolites which its exact mass value is equals to given mass value 564.3312
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PA(8:0/18:0)
PA(8:0/18:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/18:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of stearic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(10:0/i-16:0)
PA(10:0/i-16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/i-16:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of isohexadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/i-18:0)
PA(8:0/i-18:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/i-18:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of isooctadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(a-13:0/a-13:0)
PA(a-13:0/a-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-13:0/a-13:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of anteisotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(a-13:0/i-13:0)
PA(a-13:0/i-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-13:0/i-13:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-12:0/i-14:0)
PA(i-12:0/i-14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-12:0/i-14:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isotetradecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-13:0/a-13:0)
PA(i-13:0/a-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-13:0/a-13:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of anteisotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-13:0/i-13:0)
PA(i-13:0/i-13:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-13:0/i-13:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isotridecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-14:0/i-12:0)
PA(i-14:0/i-12:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-14:0/i-12:0), in particular, consists of one chain of isotetradecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
Butyloxycarbonyl-leucyl-glycyl-arginine-4-nitroanilide
(S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide
N-T-Boc-leu-gly-arg P-nitroanilide
Valnemulin
Macrolactin C
Macrolactin R
3alpha-Angeloyloxy-2-hydroxy-13-oxo-14,15-nor-ent-labda-7-en-2-O-beta-[fucopyranoside-4-O-acetate]
8-Hydroxymanzamine A
An alkaloid that is manzamine A with a hydroxy substituent at position 8. Isolated from Pachypellina and Acanthostrongylophora, it exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).
3beta-beta-D-Cymaropyranosyloxy-5,14,21-trihydroxy-24-nor-5beta,14beta-chol-20(22)t-en-19,23-disaeure-23=>21-lacton|3beta-beta-D-cymaropyranosyloxy-5,14,21-trihydroxy-24-nor-5beta,14beta-chol-20(22)t-ene-19,23-dioic acid-23=>21-lactone|cymarin-19-carboxylic acid
(+)-8-hydroxymanzamine A|(-)-8-hydroxymanzamine A|6-hydroxymanzamine A|8-hydroxymanzamine|8-Hydroxymanzamine A
(25S)-2beta-(alpha-L-arabinopyranosyloxy)-5beta-spirostan-3alpha-ol, Yononin|(25S)-2beta--5beta-spirostan-3alpha-ol, Yononin
(1beta,3beta,5beta,25S)-3-hydroxyspirostan-1-yl beta-D-xylopyranoside|(1beta,3beta,5beta,25S)-spirostan-1,3-diol 1-(beta-D-xylopyranoside)|rhodeasapogenin 1-(beta-D-xylopyranoside)
2beta,3alpha,14alpha,15beta,16-Pentacetoxy-ent-pimar-7-ene
14beta,16beta-dihydroxy-3beta-[(beta-D-glucopyranosyl)oxy]-5beta-bufa-20,22-dienolide|tigencaoside A
(22S,25S)-16beta,22,26-trihydroxycholest-4-en-3-one-16-O-beta-D-xylopyranosie
2,12-bis-O-(beta-D-glucopyranosyl)-campherenane-2-endo,12-diol
6alpha-hydroxy-23-methoxy-16beta,23(R)-epoxy-24,25,26,27-tetranor-9,-19-cyclolanosta-3-O-beta-xyloside|bicusposide B
(1R*,2R*,3E,11R*,12S*)-2,18-O-diacetyl-16-O-(3-hydroxy-3-methylglutaryl)-2,16,18-trihydroxydolabella-3,8(17)-dien-7-one
Muricatetrocin B|Muricatin B|O-[alpha-L-Rhamnopyranosyl(1鈥樏傗垎4)-alpha-L-rhamnopyranoside]-(S)-11-Hydroxyhexadecanoic acid
(11S*)-6alpha-Acetoxy-7beta,11-diisobutyryloxy-1beta,8beta-dihydroxy-4(18),13-neoclerodadien-15,16-olide|Scuterulein A
6alpha-O-beta-D-xylopyranosyl-(25R)-5alpha-spirostan-3beta-ol|6alpha-O-beta-xylopyranosyl-(25R)-5alpha-spirostan-3beta-ol|saponin Sc-3|SC-3
Arg Tyr Ala Arg
Tyr Val Arg Lys
Val Lys Tyr Arg
Tyr Gln Val Arg
Arg Tyr Val Lys
Ala Arg Arg Tyr
Ala Arg Tyr Arg
Ala Tyr Arg Arg
Asp Phe Lys Arg
Asp Phe Arg Lys
Asp Lys Phe Arg
Asp Lys Arg Phe
Asp Arg Phe Lys
Asp Arg Lys Phe
Phe Asp Lys Arg
Phe Asp Arg Lys
Phe Lys Asp Arg
Phe Lys Arg Asp
Phe Arg Asp Lys
Phe Arg Lys Asp
Phe Arg Arg Ser
Phe Arg Ser Arg
Phe Ser Arg Arg
His Pro Arg Arg
His Arg Pro Arg
His Arg Arg Pro
Ile Asn Arg Tyr
Ile Asn Tyr Arg
Ile Arg Asn Tyr
Ile Arg Tyr Asn
Ile Tyr Asn Arg
Ile Tyr Arg Asn
Lys Asp Phe Arg
Lys Asp Arg Phe
Lys Phe Asp Arg
Lys Phe Arg Asp
Lys Met Met Arg
Lys Met Arg Met
Lys Arg Asp Phe
Lys Arg Phe Asp
Lys Arg Met Met
Lys Arg Val Tyr
Lys Arg Tyr Val
Lys Val Arg Tyr
Lys Val Tyr Arg
Lys Tyr Arg Val
Lys Tyr Val Arg
Leu Asn Arg Tyr
Leu Asn Tyr Arg
Leu Arg Asn Tyr
Leu Arg Tyr Asn
Leu Tyr Asn Arg
Leu Tyr Arg Asn
Met Lys Met Arg
Met Lys Arg Met
Met Met Lys Arg
Met Met Arg Lys
Met Arg Lys Met
Met Arg Met Lys
Asn Ile Arg Tyr
Asn Ile Tyr Arg
Asn Leu Arg Tyr
Asn Leu Tyr Arg
Asn Arg Ile Tyr
Asn Arg Leu Tyr
Asn Arg Tyr Ile
Asn Arg Tyr Leu
Asn Tyr Ile Arg
Asn Tyr Leu Arg
Asn Tyr Arg Ile
Asn Tyr Arg Leu
Pro His Arg Arg
Pro Arg His Arg
Pro Arg Arg His
Gln Arg Val Tyr
Gln Arg Tyr Val
Gln Val Arg Tyr
Gln Val Tyr Arg
Gln Tyr Arg Val
Gln Tyr Val Arg
Arg Ala Arg Tyr
Arg Ala Tyr Arg
Arg Asp Phe Lys
Arg Asp Lys Phe
Arg Phe Asp Lys
Arg Phe Lys Asp
Arg Phe Arg Ser
Arg Phe Ser Arg
Arg His Pro Arg
Arg His Arg Pro
Arg Ile Asn Tyr
Arg Ile Tyr Asn
Arg Lys Asp Phe
Arg Lys Phe Asp
Arg Lys Met Met
Arg Lys Val Tyr
Arg Lys Tyr Val
Arg Leu Asn Tyr
Arg Leu Tyr Asn
Arg Met Lys Met
Arg Met Met Lys
Arg Asn Ile Tyr
Arg Asn Leu Tyr
Arg Asn Tyr Ile
Arg Asn Tyr Leu
Arg Pro His Arg
Arg Pro Arg His
Arg Gln Val Tyr
Arg Gln Tyr Val
Arg Arg Ala Tyr
Arg Arg Phe Ser
Arg Arg His Pro
Arg Arg Pro His
Arg Arg Ser Phe
Arg Arg Tyr Ala
Arg Ser Phe Arg
Arg Ser Arg Phe
Arg Val Lys Tyr
Arg Val Gln Tyr
Arg Val Tyr Lys
Arg Val Tyr Gln
Arg Tyr Ile Asn
Arg Tyr Lys Val
Arg Tyr Leu Asn
Arg Tyr Asn Ile
Arg Tyr Asn Leu
Arg Tyr Gln Val
Arg Tyr Arg Ala
Arg Tyr Val Gln
Ser Phe Arg Arg
Ser Arg Phe Arg
Ser Arg Arg Phe
Val Lys Arg Tyr
Val Gln Arg Tyr
Val Gln Tyr Arg
Val Arg Lys Tyr
Val Arg Gln Tyr
Val Arg Tyr Lys
Val Arg Tyr Gln
Val Tyr Lys Arg
Val Tyr Gln Arg
Val Tyr Arg Lys
Val Tyr Arg Gln
Tyr Ala Arg Arg
Tyr Ile Asn Arg
Tyr Ile Arg Asn
Tyr Lys Arg Val
Tyr Lys Val Arg
Tyr Leu Asn Arg
Tyr Leu Arg Asn
Tyr Asn Ile Arg
Tyr Asn Leu Arg
Tyr Asn Arg Ile
Tyr Asn Arg Leu
Tyr Gln Arg Val
Tyr Arg Ala Arg
Tyr Arg Ile Asn
Tyr Arg Lys Val
Tyr Arg Leu Asn
Tyr Arg Asn Ile
Tyr Arg Asn Leu
Tyr Arg Gln Val
Tyr Arg Arg Ala
Tyr Arg Val Lys
Tyr Arg Val Gln
Tyr Val Lys Arg
Tyr Val Gln Arg
Tyr Val Arg Gln
Macrolactin B
Macrolactin Q
3-O(alpha-L-rhamnopyranosyl)-3beta,5beta,14beta,16beta-tetrahydroxy-bufa-20,22-dienolide
17-(nonylphenoxy)-3,6,9,12,15-pentaoxaheptadecan-1-yl dihydrogen phosphate
Dansyl-DL-aspartic acid bis(cyclohexylammonium) salt
FMOC-(3S,4S)-4-AMINO-3-HYDROXY-5-METHYL-HEXANOIC ACID DCHA
(1r)-2-(Dodecanoyloxy)-1-[(Phosphonooxy)methyl]ethyl Tetradecanoate
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] hexadecanoate
(S)-N-((R)-1-(Benzo[d][1,3]dioxol-5-yl)butyl)-3,3-diethyl-2-(4-(4-methylpiperazine-1-carbonyl)phenoxy)-4-oxoazetidine-1-carboxamide
6-hydroxymanzamine A
An alkaloid that is manzamine A with a hydroxy substituent at position 6. Isolated from Haliclona and Acanthostrongylophora, it exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).
1-[(1R)-2-[(3,5-dimethoxyphenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-(4-morpholinyl)ethanone
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
1-[(1S)-2-[(3,5-dimethoxyphenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-2-(4-morpholinyl)ethanone
2-[[(2R)-2-acetyloxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-2-acetyloxy-3-[(E)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2R)-3-acetyloxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (13Z,16Z)-docosa-13,16-dienoate
(2S,3S)-3-Benzyloxy-1-(tert-butyldimethylsilyloxy)-4-(tert-butyldiphenylsilyloxy)-2-butanol
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) tricosanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) henicosanoate
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) nonadecanoate
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) octadecanoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) icosanoate
(1-Nonanoyloxy-3-phosphonooxypropan-2-yl) heptadecanoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
(1-Acetyloxy-3-phosphonooxypropan-2-yl) tetracosanoate
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) docosanoate
(3-Phosphonooxy-2-tridecanoyloxypropyl) tridecanoate
(1-Decanoyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
(1-Phosphonooxy-3-undecanoyloxypropan-2-yl) pentadecanoate
(1-Dodecanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] pentadecanoate
[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] pentadecanoate
(2R,3R)-1-[tert-butyl(dimethyl)silyl]oxy-4-[tert-butyl(diphenyl)silyl]oxy-3-phenylmethoxybutan-2-ol
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] hexadecanoate
2-[[2-[(Z)-heptadec-9-enoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-hexanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-acetyloxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-heptanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(Z)-pentadec-9-enoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-butanoyloxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-sn-glycerol)
(1r,2r,4s,12r,13r,16z)-13-hydroxy-25-{9h-pyrido[3,4-b]indol-1-yl}-11,22-diazapentacyclo[11.11.2.1²,²².0²,¹².0⁴,¹¹]heptacosa-16,25-dien-7-one
3-(acetyloxy)-5-hydroxy-6-(hydroxymethyl)-2-(2,3,4-trihydroxybutoxy)oxan-4-yl hexadecanoate
(1'r,2's,3r,5's,9'r,12's,13's,16's,18's)-2',18'-dihydroxy-16'-{[(2r,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-5-oxo-7'-oxaspiro[oxolane-3,6'-pentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosane]-13'-carbaldehyde
(2r,3r,4s,5s,6r)-2-{[(1s,3ar,4r,5r,7as)-5-isopropyl-7a-methyl-4-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydroinden-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-(hydroxymethyl)-6-{[5-isopropyl-7a-methyl-4-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydroinden-1-yl]methoxy}oxane-3,4,5-triol
(3ar,7s,16as)-2,7-dihydroxy-6,10,14,16a-tetramethyl-3-[(2s)-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl]-3ah,4h,7h,8h,9h,12h,13h,16h-cyclopenta[15]annulen-1-one
2-{3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-(3-ethyl-5-hydroxy-4-methyloxolan-2-yl)-2-hydroxypropyl acetate
4-(3a-hydroxy-7-{[5-hydroxy-6-(hydroxymethyl)-3,4-dimethoxyoxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl)-5h-furan-2-one
(17z,19z,21z,23z,25z)-3-ethyl-4,6,10,12,14,16-hexahydroxy-15,27,28-trimethyl-1-oxacyclooctacosa-17,19,21,23,25-pentaen-2-one
5-{2h,3h,3ah,6ah-furo[2,3-b]furan-2-ylmethyl}-8-(acetyloxy)-8a-[(acetyloxy)methyl]-3-hydroxy-5,6-dimethyl-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-2-yl 2-methylbutanoate
5-{[4-(acetyloxy)-1-[2-(acetyloxy)propan-2-yl]-3a-methyl-10-methylidene-9-oxo-1h,2h,3h,4h,7h,8h,11h,12h,12ah-cyclopenta[11]annulen-6-yl]methoxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
(2r,3s,4s,5s,6s)-2-{[(1s,3ar,4r,5r,7as)-5-isopropyl-7a-methyl-4-({[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydroinden-1-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3a,5a-dihydroxy-7-[(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy]-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carboxylic acid
3,17-bisdeoxo-3,17-dihydroxypenisimplicin a
{"Ingredient_id": "HBIN006969","Ingredient_name": "3,17-bisdeoxo-3,17-dihydroxypenisimplicin a","Alias": "NA","Ingredient_formula": "C30H44O10","Ingredient_Smile": "CC(=O)OC1C2C(C(CCC2(C3CC(=C)C4(C(C3(C1OC(=O)C)C)C(=O)OC(C4O)(C)C(=O)OC)C)C)O)(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2441","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}